 |
|
MAFLD enhances clinical practice for liver disease in the Asia-Pacific region
Takumi Kawaguchi, Tsubasa Tsutsumi, Dan Nakano, Mohammed Eslam, Jacob George, Takuji Torimura
Clin Mol Hepatol. 2022;28(2):150-163. Published online 2021 Nov 10 DOI: https://doi.org/10.3350/cmh.2021.0310
|
|
Citations to this article as recorded by
 The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease
Mohammed Eslam, Jian-Gao Fan, Ming-Lung Yu, Vincent Wai-Sun Wong, Ian Homer Cua, Chun-Jen Liu, Tawesak Tanwandee, Rino Gani, Wai-Kay Seto, Shahinul Alam, Dan Yock Young, Saeed Hamid, Ming-Hua Zheng, Takumi Kawaguchi, Wah-Kheong Chan, Diana Payawal, Soek-S
Hepatology International.2025;[Epub] CrossRef Prevalence of Metabolic‐Associated Steatotic Liver Disease in Patients With Primary Aldosteronism
Irene Tizianel, Alberto Madinelli, Filippo Crimì, Mattia Barbot, Simona Censi, Chiara Sabbadin, Filippo Ceccato
Clinical Endocrinology.2025;[Epub] CrossRef Prevalence of Non-alcoholic Fatty Liver Disease Detected by Computed Tomography in the General Population Compared with Ultrasonography
Yuki Ito, Kentaro Yoshioka, Kazuhiko Hayashi, Yuko Shimizu, Ryo Fujimoto, Ryosuke Yamane, Michiyo Yoshizaki, Go Kajikawa, Taro Mizutani, Hidemi Goto
Internal Medicine.2024; 63(2): 159. CrossRef Impact of non‐obese metabolic dysfunction‐associated fatty liver disease on risk factors for the recurrence of esophageal squamous cell carcinoma treated with endoscopic submucosal dissection: A multicenter study
Shuhei Fukunaga, Michita Mukasa, Tomoyuki Nakane, Dan Nakano, Tsubasa Tsutsumi, Tomonori Chou, Hiroshi Tanaka, Daiki Hayashi, Shinpei Minami, Akihiro Ohuchi, Tsutomu Nagata, Kota Takaki, Hiroshi Takaki, Ichiro Miyajima, Ryuichi Nouno, Toshihiro Araki, Tak
Hepatology Research.2024; 54(2): 201. CrossRef Metabolic management after sustained virologic response in elderly patients with hepatitis C virus: A multicenter study
Tomoya Sano, Keisuke Amano, Tatsuya Ide, Hiroshi Isoda, Yuichi Honma, Yasuyo Morita, Yoichi Yano, Hiroki Nakamura, Satoshi Itano, Ichiro Miyajima, Miki Shirachi, Reiichiro Kuwahara, Miki Ohno, Toshihiro Kawaguchi, Tsubasa Tsutsumi, Dan Nakano, Teruko Arin
Hepatology Research.2024; 54(4): 326. CrossRef Air pollution associate with advanced hepatic fibrosis among patients with chronic liver disease
Tyng‐Yuan Jang, Chi‐Chang Ho, Po‐Cheng Liang, Chih‐Da Wu, Yu‐Ju Wei, Pei‐Chien Tsai, Po‐Yao Hsu, Ming‐Yen Hsieh, Yi‐Hung Lin, Meng‐Hsuan Hsieh, Chih‐Wen Wang, Jeng‐Fu Yang, Ming‐Lun Yeh, Chung‐Feng Huang, Wan‐Long Chuang, Jee‐Fu Huang, Ya‐Yun Cheng, Chia‐
The Kaohsiung Journal of Medical Sciences.2024; 40(3): 304. CrossRef Impact of metabolic dysfunction-associated fatty liver disease on liver transplant recipients with hepatitis B virus-related hepatocellular carcinoma
Ji-Qiao Zhu, Xiao-Yong Ye, Shi-Wei Yang, Jia-Zong Liu, Zhang-Yong Ren, Ya-Nan Jia, Zhe Liu, Cheng Ding, Jian-Tao Kou, Xian-Liang Li, Dong-Dong Han, Qiang He
European Journal of Clinical Nutrition.2024; 78(2): 107. CrossRef Influence of metabolic dysfunction-associated fatty liver disease on the prognosis of patients with HBV-related acute-on-chronic liver failure
Rui-Min Lai, Li-Xi Yao, Shan Lin, Jia-Hui Zhou, Bing-Ping Liu, Zhao-Yi Liang, Tianbin Chen, Jia-Ji Jiang, Qi Zheng, Yueyong Zhu
Expert Review of Gastroenterology & Hepatology.2024; 18(1-3): 103. CrossRef Mortality in metabolic dysfunction-associated steatotic liver disease: A nationwide population-based cohort study
Eugene Han, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha, Sang Hoon Ahn, Yong-ho Lee, Seung Up Kim
Metabolism.2024; 152: 155789. CrossRef Impact of metabolic dysfunction‐associated fatty liver disease on the incidence of Helicobacter pylori‐negative gastric cancer
Tomoyuki Nakane, Shuhei Fukunaga, Dan Nakano, Tsubasa Tsutsumi, Hiroshi Tanaka, Tomonori Chou, Shinpei Minami, Akihiro Ohuchi, Tsutomu Nagata, Kota Takaki, Hiroshi Takaki, Ichiro Miyajima, Ryuichi Nouno, Shinobu Yoshinaga, Michita Mukasa, Yoshinobu Okabe,
Hepatology Research.2024; 54(6): 540. CrossRef Gut microbiota-derived indole compounds attenuate metabolic dysfunction-associated steatotic liver disease by improving fat metabolism and inflammation
Byeong Hyun Min, Shivani Devi, Goo Hyun Kwon, Haripriya Gupta, Jin-Ju Jeong, Satya Priya Sharma, Sung-Min Won, Ki-Kwang Oh, Sang Jun Yoon, Hee Jin Park, Jung A Eom, Min Kyo Jeong, Ji Ye Hyun, Nattan Stalin, Tae-Sik Park, Jieun Choi, Do Yup Lee, Sang Hak H
Gut Microbes.2024;[Epub] CrossRef Association between life’s essential 8 and metabolic dysfunction-associated steatotic liver disease among US adults
Zheng Wang, Bohan Huang, Yixuan Ding, Feng Cao, Fei Li, Prof Fei Li
Archives of Public Health.2024;[Epub] CrossRef Translational research on drug development and biomarker discovery for hepatocellular carcinoma
Valerie Chew, Chien-Huai Chuang, Chiun Hsu
Journal of Biomedical Science.2024;[Epub] CrossRef High prevalence of fatty liver and its association with metabolic syndrome among rural adults with chronic hepatitis C: Implications for primary healthcare
Ta-Jen Wang, Mei-Yen Chen, Yu-Chih Lin, Wen-Nan Chiu, Tung-Jung Huang, Hsu-Huei Weng
BMC Public Health.2024;[Epub] CrossRef Extent to which weight loss contributes to improving metabolic dysfunction-associated and metabolic and alcohol related/associated steatotic liver disease: a study on Japanese participants undergoing health checkups
Tatsuya Fukuda, Takahiro Okamoto, Takahiro Fukaishi, Akio Kawakami, Makoto Tanaka, Tetsuya Yamada, Koshiro Monzen
Frontiers in Endocrinology.2024;[Epub] CrossRef MAFLD criteria are better than MASLD criteria at predicting the risk of chronic kidney disease
Ziyan Pan, Moutaz Derbala, Khalid AlNaamani, Hasmik Ghazinian, Jian-Gao Fan, Mohammed Eslam
Annals of Hepatology.2024; 29(5): 101512. CrossRef MAFLD identifies patients with significant hepatic fibrosis better than MASLD
Ziyan Pan, Said A. Al-Busafi, Maheeba Abdulla, Yasser Fouad, Giada Sebastiani, Mohammed Eslam
Hepatology International.2024; 18(3): 964. CrossRef MAFLD: an ideal framework for understanding disease phenotype in individuals of normal weight
Ziyan Pan, Maryam Al Khatry, Ming-Lung Yu, Ashok Choudhury, Giada Sebastiani, Saleh A. Alqahtani, Mohammed Eslam
Therapeutic Advances in Endocrinology and Metabolism.2024;[Epub] CrossRef MAFLD: from a disease framework to patient care
Mohammed Eslam, Jacob George
Hepatology International.2024; 18(S2): 823. CrossRef Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis
Harry Crane, Guy D. Eslick, Cameron Gofton, Anjiya Shaikh, George Cholankeril, Mark Cheah, Jian-Hong Zhong, Gianluca Svegliati-Baroni, Alessandro Vitale, Beom Kyung Kim, Sang Hoon Ahn, Mi Na Kim, Simone I Strasser, Jacob George
Clinical and Molecular Hepatology.2024; 30(3): 436. CrossRef Effects of luseogliflozin on suspected MASLD in patients with diabetes: a pooled meta-analysis of phase III clinical trials
Takumi Kawaguchi, Kenta Murotani, Hiromitsu Kajiyama, Hitoshi Obara, Hironori Yamaguchi, Yuko Toyofuku, Fumi Kaneko, Yutaka Seino, Saeko Uchida
Journal of Gastroenterology.2024; 59(9): 836. CrossRef Metabolic dysfunction-associated fatty liver disease is a ubiquitous latent cofactor in viral- and alcoholic-related hepatocellular carcinoma: Editorial on “Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular c
Toru Nakamura, Masahito Nakano, Tsubasa Tsutsumi, Keisuke Amano, Takumi Kawaguchi
Clinical and Molecular Hepatology.2024; 30(4): 705. CrossRef Pemafibrate Reduced Liver Stiffness in Patients with Metabolic Dysfunction-associated Steatotic Liver Disease Complicated with Hyperlipidemia and Liver Fibrosis with a Fibrosis-4 Index Above 1.3
Tatsuki Ichikawa, Mio Yamashima, Shinobu Yamamichi, Makiko Koike, Yusuke Nakano, Hiroyuki Yajima, Osamu Miyazaki, Tomonari Ikeda, Takuma Okamura, Naohiro Komatsu, Sayuri Sugio, Miruki Yoshino, Hisamitsu Miyaaki
Internal Medicine.2024;[Epub] CrossRef Paradigm shift in steatotic liver disease (SLD): from NAFLD to MASLD
Masato Yoneda, Takashi Kobayashi, Michihiro Iwaki, Naohiro Wada, Asako Nogami, Hirokazu Takahashi, Atsushi Nakajima
Kanzo.2024; 65(9): 420. CrossRef Overlapping group between non‐alcoholic fatty liver disease and metabolic associated fatty liver disease better for liver research
Yu‐Ming Cheng, Tsung‐Han Hsieh, Chia‐Chi Wang, Jia‐Horng Kao
JGH Open.2024;[Epub] CrossRef Metabolic dysfunction-associated fatty liver disease related hepatocellular carcinoma in China: An increasing problem: Letter to the edior on “Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A sy
Xiangyu Wu, Wenjing Ni, Qianqian Chen, Junping Shi, Jie Li
Clinical and Molecular Hepatology.2024; 30(4): 965. CrossRef Effects of SGLT2 inhibitors on the onset of esophageal varices and extrahepatic cancer in type 2 diabetic patients with suspected MASLD: a nationwide database study in Japan
Takumi Kawaguchi, Yoshiyuki Fujishima, Daisuke Wakasugi, Fusayo Io, Yuri Sato, Saeko Uchida, Yukiko Kitajima
Journal of Gastroenterology.2024; 59(12): 1120. CrossRef Carnitine palmitoyltransferase-II inactivity promotes malignant progression of metabolic dysfunction-associated fatty liver disease via liver cancer stem cell activation
Ling-Ling Wang, Yu-Ming Lu, Yi-Han Wang, Yi-Fan Wang, Rong-Fei Fang, Wen-Li Sai, Deng-Fu Yao, Min Yao
World Journal of Gastroenterology.2024; 30(47): 5055. CrossRef The beneficial impact of metabolic dysfunction‐associated fatty liver disease on lenvatinib treatment in patients with non‐viral hepatocellular carcinoma
Shigeo Shimose, Atsushi Hiraoka, Andrea Casadei‐Gardini, Tsubasa Tsutsumi, Dan Nakano, Hideki Iwamoto, Fujimasa Tada, Margherita Rimini, Masatoshi Tanaka, Takuji Torimura, Hideya Suga, Hideko Ohama, Valentina Burgio, Takashi Niizeki, Etsuko Moriyama, Hiro
Hepatology Research.2023; 53(2): 104. CrossRef Metabolic-associated fatty liver disease and the risk of cardiovascular disease
Pengwei Zhang, Xianhui Dong, Wei Zhang, Shiyin Wang, Chen Chen, Jiake Tang, Yao You, Siqi Hu, Shenghui Zhang, Chunyi Wang, Wen Wen, Mengyun Zhou, Tao Tan, Guanming Qi, Li Li, Mingwei Wang
Clinics and Research in Hepatology and Gastroenterology.2023; 47(1): 102063. CrossRef Utility of Indices Obtained during Medical Checkups for Predicting Fatty Liver Disease in Non-obese People
Naoya Otsubo, Tatsuya Fukuda, Genhin Cho, Fumiaki Ishibashi, Tetsuya Yamada, Koshiro Monzen
Internal Medicine.2023; 62(16): 2307. CrossRef Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than non‐alcoholic fatty liver disease
Ho Soo Chun, Minjong Lee, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Yong‐Ho Lee, Ji‐Hye Kim, Seung Up Kim
Liver International.2023; 43(3): 608. CrossRef New Concept of Fatty Liver: Metabolic dysfunction-associated fatty liver disease
Takumi Kawaguchi
Kanzo.2023; 64(2): 33. CrossRef The Inter-Organ Crosstalk Reveals an Inevitable Link between MAFLD and Extrahepatic Diseases
Tsubasa Tsutsumi, Dan Nakano, Ryuki Hashida, Tomoya Sano, Machiko Kawaguchi, Keisuke Amano, Takumi Kawaguchi
Nutrients.2023; 15(5): 1123. CrossRef MAFLD: How is it different from NAFLD?
Cameron Gofton, Yadhavan Upendran, Ming-Hua Zheng, Jacob George
Clinical and Molecular Hepatology.2023; 29(Suppl): S17. CrossRef The effects of moderate alcohol consumption on non-alcoholic fatty liver disease
Hyunwoo Oh, Won Sohn, Yong Kyun Cho
Clinical and Molecular Hepatology.2023; 29(Suppl): S261. CrossRef Treatment efficacy of diet and exercise program for fatty liver and pretreatment predictors
Norio Akuta, Yusuke Kawamura, Shunichiro Fujiyama, Kenichi Nakamichi, Eiji Saegusa, Hidetoshi Ogura, Masaki Kato, Etsuko Doi, Naoko Inoue, Hitomi Sezaki, Tetsuya Hosaka, Mariko Kobayashi, Satoshi Saitoh, Yasuji Arase, Kenji Ikeda, Yoshiyuki Suzuki, Hiromi
Hepatology Research.2023; 53(7): 607. CrossRef Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives
Shang-Chin Huang, Chun-Jen Liu
Clinical and Molecular Hepatology.2023; 29(2): 320. CrossRef How many times should we repeat measurements of the ultrasound-guided attenuation parameter for evaluating hepatic steatosis?
Duck Min Seo, Sang Min Lee, Ji Won Park, Min-Jeong Kim, Hong Il Ha, Sun-Young Park, Kwanseop Lee
Ultrasonography.2023; 42(2): 227. CrossRef Prevalence and Risk Factors of Metabolic-Associated Fatty Liver Disease Among Hospital Staff
Daya Zhang, Lijun Zhang, Shiju Chen, Runxiang Chen, Xiaodong Zhang, Feihu Bai
Diabetes, Metabolic Syndrome and Obesity.2023; Volume 16: 1221. CrossRef Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Japanese perspective
Hironori Koga, Hideki Iwamoto, Hiroyuki Suzuki, Shigeo Shimose, Masahito Nakano, Takumi Kawaguchi
Clinical and Molecular Hepatology.2023; 29(2): 242. CrossRef Characteristics and long-term mortality of patients with non-MAFLD hepatic steatosis
Hong Fan, Zhenqiu Liu, Pengyan Zhang, Sheng Wu, Xinyu Han, Yiwen Huang, Yichen Zhu, Xingdong Chen, Tiejun Zhang
Hepatology International.2023; 17(3): 615. CrossRef Changing the nomenclature from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease is more than a change in terminology
Eileen Laurel Yoon, Dae Won Jun
Clinical and Molecular Hepatology.2023; 29(2): 371. CrossRef Smoking Increases the Risk of Hepatocellular Carcinoma and Cardiovascular Disease in Patients with Metabolic-Associated Fatty Liver Disease
Jeong-Ju Yoo, Man Young Park, Eun Ju Cho, Su Jong Yu, Sang Gyune Kim, Yoon Jun Kim, Young Seok Kim, Jung-Hwan Yoon
Journal of Clinical Medicine.2023; 12(9): 3336. CrossRef Influence of diabetes mellitus and effectiveness of metformin on hepatocellular carcinoma
Masafumi Ono, Koji Fujita, Kiyoyuki Kobayashi, Tsutomu Masaki
Hepatology Research.2023; 53(7): 579. CrossRef MAFLD might be better in identifying subjects with sarcopenia or cardiovascular risk than NAFLD: A nationwide study
Eugene Han, Ho Soo Chun, Yong‐ho Lee, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Byung‐Wan Lee, Eun Seok Kang, Bong‐Soo Cha, Sang Hoon Ahn, Seung Up Kim
Journal of Gastroenterology and Hepatology.2023; 38(9): 1598. CrossRef Transient elastography with controlled attenuation parameter versus two-dimensional shear wave elastography with attenuation imaging for the evaluation of hepatic steatosis and fibrosis in NAFLD
Jung Wook Seo, Youe Ree Kim, Jong Keon Jang, So Yeon Kim, Young Youn Cho, Eun Sun Lee, Dong Ho Lee
Ultrasonography.2023; 42(3): 421. CrossRef Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma
Byeong Geun Song, Sung Chul Choi, Myung Ji Goh, Wonseok Kang, Dong Hyun Sinn, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Seung Woon Paik
JHEP Reports.2023; 5(9): 100810. CrossRef The impact of concomitant metabolic dysfunction-associated fatty liver disease on adverse outcomes in patients with hepatitis B cirrhosis: a propensity score matching study
Xinyu Wang, Shuhang Wei, Yingnan Wei, Xueqi Wang, Feng Xiao, Yuemin Feng, Qiang Zhu
European Journal of Gastroenterology & Hepatology.2023; 35(8): 889. CrossRef MAFLD: an optimal framework for understanding liver cancer phenotypes
Harry Crane, Cameron Gofton, Ankur Sharma, Jacob George
Journal of Gastroenterology.2023; 58(10): 947. CrossRef Comparative Analysis of Atezolizumab Plus Bevacizumab and Hepatic Artery Infusion Chemotherapy in Unresectable Hepatocellular Carcinoma: A Multicenter, Propensity Score Study
Ji Kim, Hee-Chul Nam, Chang-Wook Kim, Hee Cho, Jae-Sung Yoo, Ji Han, Jeong Jang, Jong Choi, Seung Yoon, Hyun Yang, Si Bae, Suho Kim, Jung Oh, Ho Chun, Chang Jeon, Jaegyoon Ahn, Pil Sung
Cancers.2023; 15(17): 4233. CrossRef What Is in a Name: from NAFLD to MAFLD and MASLD—Unraveling the Complexities and Implications
Mariana M. Ramírez-Mejía, Nahum Méndez-Sánchez
Current Hepatology Reports.2023; 22(4): 221. CrossRef Multi-system diseases and death trajectory of metabolic dysfunction-associated fatty liver disease: findings from the UK Biobank
Yu Jia, Dongze Li, Yi You, Jing Yu, Wenli Jiang, Yi Liu, Rui Zeng, Zhi Wan, Yi Lei, Xiaoyang Liao
BMC Medicine.2023;[Epub] CrossRef Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease
Hyeok-Hee Lee, Han Ah Lee, Eun-Jin Kim, Hwi Young Kim, Hyeon Chang Kim, Sang Hoon Ahn, Hokyou Lee, Seung Up Kim
Gut.2023; : gutjnl-2023-331003. CrossRef Impact of anthropometric parameters on outcomes in Asians with metabolic dysfunction‐associated fatty liver disease
Kyu Yeon Choi, Tae Yeon Kim, Young Eun Chon, Mi Na Kim, Joo Ho Lee, Seong Gyu Hwang, Jiwoo Lee, Mi Kyung Kwak, Eun‐Gyoung Hong, Yun Mi Choi, Yeonjung Ha
Journal of Cachexia, Sarcopenia and Muscle.2023; 14(6): 2747. CrossRef Ultrasonographic Assessment of Tissue Stiffness: Recent Progress in Transient Elastography and Shear Wave Elastography in the Liver and Various Organs
MASAHITO NAKANO, RYOKO KUROMATSU, TAKUMI KAWAGUCHI
The Kurume Medical Journal.2023; 70(1.2): 1. CrossRef Metabolic dysfunction-associated fatty liver disease — How relevant is this to primary care physicians and diabetologists?
Chi-Ho Lee
Primary Care Diabetes.2022;[Epub] CrossRef Atherosclerotic cardiovascular disease in non‐metabolic nonalcoholic fatty liver disease
Tsubasa Tsutsumi, Takumi Kawaguchi, Dan Nakano, Takuji Torimura
Hepatology Research.2022; 52(3): 317. CrossRef Effects of interleukin-17 inhibitors on hepatic fibrosis index in patients with psoriasis and metabolic dysfunction-associated fatty liver disease: Directed acyclic graphs
Saori Takamura, Yuichi Teraki, Eri Katayama, Takumi Kawaguchi, Machiko Kawaguchi, Dan Nakano, Tsubasa Tsutsumi, Sumiko Nagoshi, Takekuni Nakama, Takuji Torimura
Clinical and Molecular Hepatology.2022; 28(2): 269. CrossRef MAFLD Predicts the Risk of Cardiovascular Disease Better than NAFLD in Asymptomatic Subjects with Health Check-Ups
Hyoeun Kim, Chan Joo Lee, Sang Hoon Ahn, Kwan Sik Lee, Byoung Kwon Lee, Su Jung Baik, Seung Up Kim, Jung Il Lee
Digestive Diseases and Sciences.2022; 67(10): 4919. CrossRef Lean/normal‐weight metabolic dysfunction‐associated fatty liver disease is a risk factor for reflux esophagitis
Shuhei Fukunaga, Dan Nakano, Tsubasa Tsutsumi, Takumi Kawaguchi, Mohammed Eslam, Shinobu Yoshinaga, Hirohiko Abe, Ryuichi Nouno, Seiya Joh, Keiichi Mitsuyama, Jacob George, Takuji Torimura
Hepatology Research.2022; 52(8): 699. CrossRef Metabolic dysfunction‐associated fatty liver disease directly related to liver fibrosis independent of insulin resistance, hyperlipidemia, and alcohol intake in morbidly obese patients
Susumu Inamine, Masayoshi Kage, Jun Akiba, Takumi Kawaguchi, Sachiyo Yoshio, Machiko Kawaguchi, Dan Nakano, Tsubasa Tsutsumi, Ryuki Hashida, Kouichi Oshiro
Hepatology Research.2022; 52(10): 841. CrossRef MAFLD, patient-centred care, and APASL
Shiv K. Sarin, Mohammed Eslam, Jian-Gao Fan, Han-Chieh Lin, Jacob George, Masao Omata
Hepatology International.2022; 16(5): 1032. CrossRef The relationship between metabolic dysfunction‐associated fatty liver disease and low muscle mass in an asymptomatic Korean population
Ji Yeon Seo, Eun Ju Cho, Min Joo Kim, Min‐Sun Kwak, Jong In Yang, Su Jin Chung, Jeong Yoon Yim, Ji Won Yoon, Goh Eun Chung
Journal of Cachexia, Sarcopenia and Muscle.2022; 13(6): 2953. CrossRef MAFLD: A quick fact check
Nahum Méndez‐Sánchez, Jian‐Gao Fan, Mohamed El‐Kassas, Marcos Girala
Liver International.2022; 42(12): 2903. CrossRef Fatty liver index as a predictor for incident type 2 diabetes in community-dwelling adults: longitudinal findings over 12 years
In-Ho Seo, Hye Sun Lee, Yong-Jae Lee
Cardiovascular Diabetology.2022;[Epub] CrossRef Utility of Human Relevant Preclinical Animal Models in Navigating NAFLD to MAFLD Paradigm
Damien Chua, Zun Siong Low, Guo Xiang Cheam, Aik Seng Ng, Nguan Soon Tan
International Journal of Molecular Sciences.2022; 23(23): 14762. CrossRef
|